Search research articles
Contact Us
Filters
Showing results (301-310 of 487) with videos related to
Page
of 49
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
January 10, 2024
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases
Solange Peters, José Trigo, Benjamin Besse, et al.
Oncotarget
|
July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
Ishwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
ESMO Open
|
November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
Andrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
Scientific Reports
|
February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
Yudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Oncotarget
|
September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
Vikas Dembla, Neeta Somaiah, Pedro Barata, et al.
BMC Cancer
|
June 13, 2021
Food and Drug Administration approvals in phase 3 Cancer clinical trials
Joseph Abi Jaoude, Ramez Kouzy, Marc Ghabach, et al.
Gynecologic Oncology Research and Practice
|
May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
Siqing Fu, Naiyi Shi, Jennifer Wheler, et al.
JCO Precision Oncology
|
September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
British Journal of Cancer
|
March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
Shuyang Yao, Filip Janku, Vivek Subbiah, et al.
Molecular Cancer Therapeutics
|
December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Page
of 49
Search research articles
Search
Showing results (301-310 of 487) with videos related to
Sort By:
Page
of 49
Lung Cancer (Amsterdam, Netherlands)
|
January 10, 2024
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases
Solange Peters, José Trigo, Benjamin Besse, et al.
Oncotarget
|
July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
Ishwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
ESMO Open
|
November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
Andrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
Scientific Reports
|
February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
Yudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Oncotarget
|
September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
Vikas Dembla, Neeta Somaiah, Pedro Barata, et al.
BMC Cancer
|
June 13, 2021
Food and Drug Administration approvals in phase 3 Cancer clinical trials
Joseph Abi Jaoude, Ramez Kouzy, Marc Ghabach, et al.
Gynecologic Oncology Research and Practice
|
May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
Siqing Fu, Naiyi Shi, Jennifer Wheler, et al.
JCO Precision Oncology
|
September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
British Journal of Cancer
|
March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
Shuyang Yao, Filip Janku, Vivek Subbiah, et al.
Molecular Cancer Therapeutics
|
December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Page
of 49